InvestSMART

Artrya Limited (ASX:AYA)

ALERT: Price-sensitive ASX Announcement for AYA
Current share price for AYA : $4.410 -0.68 (-13.36%)+
Announcement
Release
29 Jul 2026 8:37AM
Price at Release
$5.090
Full Release
download
Summary
Artrya Limited reported on its activities and financial performance for the quarter ending 30 June 2026, highlighting significant progress in commercial and clinical strategies. The company advanced its U.S. market penetration with the Salix® platform, achieving milestones such as the routine use of Salix® by Tanner Health and Northeast Georgia Health System. Artrya's strategic initiatives included real-time reimbursement workflows and the progression of the Salix® Coronary Flow module's FDA submission, targeting clearance and commercial launch in the latter half of 2026. Financially, Artrya maintained a strong position with $44.025 million in cash and cash equivalents, excluding a $30 million term deposit. The operational strategy focused on scaling adoption and enhancing Artrya's presence in the U.S. through clinical and commercial partnerships, reinforced by the SAPPHIRE Study and a newly formed Clinical Advisory Board.
Key Points
  • Artrya's Salix® platform gains traction with U.S. foundation customers.
  • Tanner Health using Salix® routinely; Northeast Georgia Health System went live.
  • FDA submission for Salix® Coronary Flow targeted for second half of CY26.
  • SAPPHIRE Study commenced to support commercial strategy.
  • Pro forma cash position of $74.0M at 30 June 2026.
  • Operational focus on scalable implementation and reimbursement workflows.
  • Financial strategy includes $30M term deposit for treasury management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.